138 related articles for article (PubMed ID: 8252804)
1. The putative oncoprotein DEK, part of a chimera protein associated with acute myeloid leukaemia, is an autoantigen in juvenile rheumatoid arthritis.
Sierakowska H; Williams KR; Szer IS; Szer W
Clin Exp Immunol; 1993 Dec; 94(3):435-9. PubMed ID: 8252804
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene.
Murray KJ; Szer W; Grom AA; Donnelly P; Levinson JE; Giannini EH; Glass DN; Szer IS
J Rheumatol; 1997 Mar; 24(3):560-7. PubMed ID: 9058666
[TBL] [Abstract][Full Text] [Related]
3. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis.
Szer IS; Sierakowska H; Szer W
J Rheumatol; 1994 Nov; 21(11):2136-42. PubMed ID: 7869324
[TBL] [Abstract][Full Text] [Related]
4. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.
Fu GK; Grosveld G; Markovitz DM
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1811-5. PubMed ID: 9050861
[TBL] [Abstract][Full Text] [Related]
5. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.
Mor-Vaknin N; Kappes F; Dick AE; Legendre M; Damoc C; Teitz-Tennenbaum S; Kwok R; Ferrando-May E; Adams BS; Markovitz DM
Arthritis Rheum; 2011 Feb; 63(2):556-67. PubMed ID: 21280010
[TBL] [Abstract][Full Text] [Related]
6. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.
Mor-Vaknin N; Rivas M; Legendre M; Mohan S; Yuanfan Y; Mau T; Johnson A; Huang B; Zhao L; Kimura Y; Spalding SJ; Morris PW; Gottlieb BS; Onel K; Olson JC; Edelheit BS; Shishov M; Jung LK; Cassidy EA; Prahalad S; Passo MH; Beukelman T; Mehta J; Giannini EH; Adams BS; Lovell DJ; Markovitz DM
Arthritis Rheumatol; 2018 Apr; 70(4):594-605. PubMed ID: 29287303
[TBL] [Abstract][Full Text] [Related]
7. Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides.
Forero L; Zwirner NW; Fink CW; Fernández-Viña MA; Stastny P
Hum Immunol; 1998 Jul; 59(7):443-50. PubMed ID: 9684994
[TBL] [Abstract][Full Text] [Related]
8. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes.
McGarvey T; Rosonina E; McCracken S; Li Q; Arnaout R; Mientjes E; Nickerson JA; Awrey D; Greenblatt J; Grosveld G; Blencowe BJ
J Cell Biol; 2000 Jul; 150(2):309-20. PubMed ID: 10908574
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to DEK oncoprotein in systemic lupus erythematosus (SLE).
Wichmann I; Respaldiza N; Garcia-Lozano JR; Montes M; Sanchez-Roman J; Nuñez-Roldan A
Clin Exp Immunol; 2000 Mar; 119(3):530-2. PubMed ID: 10691927
[TBL] [Abstract][Full Text] [Related]
10. The DEK nuclear autoantigen is a secreted chemotactic factor.
Mor-Vaknin N; Punturieri A; Sitwala K; Faulkner N; Legendre M; Khodadoust MS; Kappes F; Ruth JH; Koch A; Glass D; Petruzzelli L; Adams BS; Markovitz DM
Mol Cell Biol; 2006 Dec; 26(24):9484-96. PubMed ID: 17030615
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to DEK oncoprotein in human inflammatory disease.
Dong X; Wang J; Kabir FN; Shaw M; Reed AM; Stein L; Andrade LE; Trevisani VF; Miller ML; Fujii T; Akizuki M; Pachman LM; Satoh M; Reeves WH
Arthritis Rheum; 2000 Jan; 43(1):85-93. PubMed ID: 10643703
[TBL] [Abstract][Full Text] [Related]
12. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to transcriptional regulation proteins DEK and ALY in a patient with systemic lupus erythematosus.
Wichmann I; Garcia-Lozano JR; Respaldiza N; Gonzalez-Escribano MF; Nuñez-Roldan A
Hum Immunol; 1999 Jan; 60(1):57-62. PubMed ID: 9952027
[TBL] [Abstract][Full Text] [Related]
14. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
Mor-Vaknin N; Saha A; Legendre M; Carmona-Rivera C; Amin MA; Rabquer BJ; Gonzales-Hernandez MJ; Jorns J; Mohan S; Yalavarthi S; Pai DA; Angevine K; Almburg SJ; Knight JS; Adams BS; Koch AE; Fox DA; Engelke DR; Kaplan MJ; Markovitz DM
Nat Commun; 2017 Feb; 8():14252. PubMed ID: 28165452
[TBL] [Abstract][Full Text] [Related]
15. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
16. Synapsin I identified as a novel brain-specific autoantigen.
Gitlits VM; Sentry JW; Matthew LS; Smith AI; Toh BH
J Investig Med; 2001 May; 49(3):276-83. PubMed ID: 11352186
[TBL] [Abstract][Full Text] [Related]
17. DEK binding to class II MHC Y-box sequences is gene- and allele-specific.
Adams BS; Cha HC; Cleary J; Haiying T; Wang H; Sitwala K; Markovitz DM
Arthritis Res Ther; 2003; 5(4):R226-33. PubMed ID: 12823858
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Adachi Y; Pavlakis GN; Copeland TD
J Biol Chem; 1994 Jan; 269(3):2258-62. PubMed ID: 8294483
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis.
Dong X; Michelis MA; Wang J; Bose R; DeLange T; Reeves WH
Arthritis Rheum; 1998 Aug; 41(8):1505-10. PubMed ID: 9704652
[TBL] [Abstract][Full Text] [Related]
20. Solution NMR structure of the N-terminal domain of the human DEK protein.
Devany M; Kappes F; Chen KM; Markovitz DM; Matsuo H
Protein Sci; 2008 Feb; 17(2):205-15. PubMed ID: 18227428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
